Emapalumab (sold under the brand name Gamifant) is a fully human monoclonal antibody medication that targets and neutralizes interferon gamma (IFNγ), a pro-inflammatory protein.
Approved for adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (pHLH) or macrophage activation syndrome (MAS) in Still’s disease.
Neutralizes free and receptor-bound IFNγ to block hyperinflammatory signaling cascades.
Dosage: Given as a 1 mg/kg intravenous (IV) infusion twice weekly alongside dexamethasone.
Side Effects: Carries risks of severe infections, hypertension, infusion reactions, and fever.
Live vaccines are contraindicated during and shortly after therapy.
Views: 1
